{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Motor+Therapy",
    "query": {
      "condition": "Oral Motor Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Motor+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T12:19:23.572Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04380142",
      "title": "Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease (PD)"
      ],
      "interventions": [
        {
          "name": "ABBV-951",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Levodopa/Carbidopa (LD/CD)",
          "type": "DRUG"
        },
        {
          "name": "Levodopa/Carbidopa (LD/CD)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-951",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2020-10-19",
      "completion_date": "2021-09-29",
      "has_results": true,
      "last_update_posted_date": "2022-11-18",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380142"
    },
    {
      "nct_id": "NCT06808984",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Agitation",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "BMS-986368",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 120,
      "start_date": "2025-06-09",
      "completion_date": "2028-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 53,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 46 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06808984"
    },
    {
      "nct_id": "NCT06609213",
      "title": "Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Gastrointestinal Intolerance",
        "Enteral Nutrition Therapy"
      ],
      "interventions": [
        {
          "name": "Medical Food",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Andrea Charvet",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2025-01-10",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 1,
      "location_summary": "Fort Lauderdale, Florida",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609213"
    },
    {
      "nct_id": "NCT00125203",
      "title": "Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type B (Myobloc)",
          "type": "DRUG"
        },
        {
          "name": "Injection of salivary glands",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2003-07",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125203"
    },
    {
      "nct_id": "NCT05797701",
      "title": "A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "SAR443820",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-07-28",
      "completion_date": "2021-09-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797701"
    },
    {
      "nct_id": "NCT03991169",
      "title": "Oral Iron in Children With Chronic Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Insufficiency",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Ferrous Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-04-19",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 2,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03991169"
    },
    {
      "nct_id": "NCT07088055",
      "title": "Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Orofacial Myofunctional Disorders",
        "Myo Munchee",
        "Oral Motor Therapy",
        "Maxillary Deficiency"
      ],
      "interventions": [
        {
          "name": "Chewing device only",
          "type": "DEVICE"
        },
        {
          "name": "Myo Munchee and Oral Motor Therapy Treatment",
          "type": "DEVICE"
        },
        {
          "name": "Oral Motor Therapy Treatment Arm",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Myo Munchee (Operations) Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "3 Years to 5 Years"
      },
      "enrollment_count": 48,
      "start_date": "2025-08-20",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07088055"
    },
    {
      "nct_id": "NCT03457753",
      "title": "Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALS"
      ],
      "interventions": [
        {
          "name": "Riluzole Oral Soluble Film",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aquestive Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-03-01",
      "completion_date": "2018-03-27",
      "has_results": false,
      "last_update_posted_date": "2019-05-13",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03457753"
    },
    {
      "nct_id": "NCT00199420",
      "title": "A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Istradefylline (KW-6002)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 580,
      "start_date": "2004-07",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 2,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00199420"
    },
    {
      "nct_id": "NCT01766336",
      "title": "A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Group 1 ELND005",
          "type": "DRUG"
        },
        {
          "name": "Group 2 ELND005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 296,
      "start_date": "2013-01",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-07-22T12:19:23.572Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766336"
    }
  ]
}